Research Model · Sample report
Sector investment thesis · HealthcareWhere should a hospital group invest in AI over the next three years?
A Research Model report for an investment committee: the evidence, the findings and what to do. Every claim is sourced, dated and rated for confidence, so the committee can see what the evidence supports and what it does not yet support.
The read
Build the data foundation first. Fund operational AI on evidence. Defer agentic AI until it earns its place.
The evidence clearly shows where to invest first: federated data harmonization and analytics infrastructure. It does not yet show how much to invest or what return to expect, so the recommendation is a phased commitment with scale-or-stop gates.Where to invest
Harmonized clinical data is the shared input for both operational and research AI, and the regulatory environment favours interoperable, FHIR-based infrastructure.
How much, at what return
The evidence base contains no cost, payback or outcome figures, and the agentic AI direction rests on early indications only.
Phase and gate
Infrastructure first, baselines before budgets, pilots with scale-or-stop criteria, and a compliance gate before any contract.
Key findings
The bottleneck is data that can’t be pooled.
- Not a shortage of AI tools. Harmonized datasets feed every downstream use, from scheduling to research, which makes infrastructure the first move.
- Two value pools, two clocks. Operational AI pays back inside the three-year window; research and real-world evidence pay back later and depend on partners. Track them as two investment lines.
- Regulation is an enabler, not a deadline. Federal interoperability rules make data flow possible, and become a direct obligation only if the group runs a health plan.
- The moat is governance, not software. Trusted data stewardship and proven compliance are the defensible assets.
- Three disqualifiers form a funding gate: data stewardship, standards and regulatory fit, applied pass/fail before any funding approval.
Recommended roadmap
Seven moves, sequenced by readiness and risk.
| Move | Owner | Timing |
|---|---|---|
| 1 · Data harmonization platform | CIO + data governance | Year 1, first |
| 2 · Baselines before budgets | CFO + CIO / CDO | Before next capital cycle |
| 3 · Rank the four AI domains | CFO + CIO | Before Year 1 budget |
| 4 · Operational pilots | COO · CMO | Year 1 |
| 5 · Compliance gate | Compliance / privacy | Before first contract |
| 6 · Alliance terms review | Strategy + legal | Before long-term commitment |
| 7 · Agentic AI gate | Investment committee | After baselines exist |
Inside the full report
What the full report covers.
- ◆Executive briefThe decision we recommend, and what the evidence supports, does not yet support, and proposes
- 01The investment thesisWhy data is the bottleneck, and the two value pools on two clocks
- 02Regulatory and market contextInteroperability, standards and real-world evidence rules, and where the moat sits
- 03Recommended roadmapSeven moves with owners and timing, plus the disqualifiers that form the funding gate
- 04Risks to manageLock-in, unproven returns, vendor selection, clinical validation and compliance
- 05Questions to confirm with your teamSix answers that sharpen the recommendation, and further research worth scoping
- AAppendix · claims ledgerEvery claim with its confidence rating and source, and how to read the evidence base
- RResearch paper and referencesThe full sector investment thesis: market structure, returns, exit dynamics, defensibility, disqualifiers tested and open questions
Request the full report.
Read the complete report, including the claims ledger and the full research paper behind the recommendation.
Produce this for your organization.
Bring your own investment question. The Research Model builds the evidence base, rates every claim and returns a recommendation your committee can act on, with your own data added as a second layer.
This sample is anonymized and summarizes a Research Model report built from public regulatory and industry sources. It is for illustration and is not investment, legal or clinical advice.